kff glp-1 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for obesity treatment as of October 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC As the popularity of GLP-1

We emphasize the importance of compassionate care and support throughout the treatment process

More progress on the weight-loss treatment front: A lot of pharmaceutical companies, particularly Novo Nordisk [which makes Ozempic and Wegovy] and Eli Lilly [which makes Zepbound], have been studying and reformulating oral weight-loss meds to improve how well theyre absorbed by the body, continues Corrado

is available at LCS MedSpa

In contrast, health plans are more likely to evaluate obesity treatment through the lens of clinical effectiveness balanced with cost-efficiency, considering the large percentage of members who would be eligible to take the drugs

However, despite these results, Novo Nordisks shares declined post-announcement, as investors had anticipated even stronger outcomes, particularly in the T2D cohort, where the efficacy lagged behind emerging triple agonists like retatrutide

Z., Yang, Y., Whiteman, M., Moore, P